Michael Morris

Michael Morris at Memorial Sloan Kettering Cancer Center has been a key investigator in the development of PSMA-targeted radioligand therapies for prostate cancer, including the VISION trial of Lu-177-PSMA-617. His work spans PSMA imaging biomarkers, patient selection criteria for radioligand therapy, and combination approaches with androgen receptor inhibition. He has contributed to regulatory submissions and clinical guideline development for PSMA-targeted therapies. His research has helped define the modern standard of care for PSMA-positive mCRPC.